11:47 AM EST - YM BioSciences Inc. : said the U.S. Food and Drug Administration (FDA) has advised the company that it may now enroll patients at U.S. clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. YM BioSciences Inc.
shares T.YM are trading up $0.09 at $1.83.
